FDA Insists on Priority Review For VMA Drug Ocriplasmin
Even though ThromboGenics NV decided not to seek a priority review of its BLA for its symptomatic vitreomacular adhesion (VMA) drug ocriplasmin, the FDA decided to bestow one on the company anyway. The Leuven, Belgium-based firm now plans to withdraw its original BLA and to re-submit the file in April. The fast-track procedure should lead to a decision within six months.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST